Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo

Autor: Keiichi Tasaka, Masahiro Sakata, Tadashi Kimura, Seiji Ogata, Kenjiro Sawada, Ken-ichirou Morishige, Shoko Shimizu, Kae Hashimoto, Masahiro Tahara
Rok vydání: 2007
Předmět:
Zdroj: Biochemical and Biophysical Research Communications. 356:72-77
ISSN: 0006-291X
DOI: 10.1016/j.bbrc.2007.02.102
Popis: Geranylgeranylacetone (GGA), an isoprenoid compound, is an anti-ulcer drug developed in Japan. In our previous study, GGA was shown to inhibit ovarian cancer invasion by attenuating Rho activation [K. Hashimoto, K. Morishige, K. Sawada, M. Tahara, S. Shimizu, M. Sakata, K. Tasaka, Y. Murata, Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro. Cancer 103 (2005) 1529-1536.]. In the present study, GGA treatment inhibited ovarian cancer progression in vitro and suppressed the tumor growth and ascites in the in vivo ovarian cancer model. In vitro analysis, treatment of cancer cells by GGA resulted in the inhibition of cancer cell proliferation, the inactivation of Ras, and the suppression of tyrosine phosphorylation of mitogen-activated protein kinase (MAPK). In conclusion, this is the first report that GGA inhibited ovarian cancer progression and the anti-tumor effect by GGA is, at least in part, derived not only from the suppression of Rho activation but also Ras-MAPK activation.
Databáze: OpenAIRE